Safety of Heterologous mRNA Vaccine Booster in Healthy Adults

Authors: Liu J , Feng S , Li J , Wu D , Cai L , Wang Y , Chen Z , Wang X , Du C , Ma X , Gou J , Xu L , Wan P , Han Y , Xu B , Dong X , Qiu D , Wang H , Zhu T and Yu Q

DOI: 10.23880/eij-16000257

Volume 7, Issue 1

Abstract

The emergence of SARS-CoV-2 variants of concern (VOCs) and the waning of vaccine-elicited neutralizing antibodies has generated significant international interest in assessments of heterologous boost vaccination. We evaluated the safety of the mRNA vaccine CS-2034 as a heterologous booster in participants who received a three-dose of the inactivated vaccines at least 6 months ago. Safety data presented here consist of solicited and unsolicited adverse events collected within 28 days after boost vaccination in participants. The heterologous booster was safe with no vaccine-related serious adverse events occurring. The overall incidence of adverse reactions within 28 days was 61.69% (504 cases), mainly grade 1 or 2 in severity. Our results suggest that heterologous boosting with mRNA vaccine CS-2034 has a favorable safety profile.

Keywords: SARS-CoV-2; Heterologous Booster; mRNA vaccine CS-2034; Safety

View PDF